MSU
UTHR icon

Maple Securities USA’s United Therapeutics UTHR Stock Holding History

Maple Securities USA’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,244
Closed -$216K – 175
2015
Q2 		$216K Buy
+1,244
New +$224K 0.02% 223

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Maple Securities USA's UTHR Position: Q3 2015 in Review

Maple Securities USA sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 1,244 shares — an estimated $216K sold.

Maple Securities USA first reported a position in UTHR in Q2 2015 and held it in 1 quarter. The position peaked at $216K in Q2 2015. 372 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

  • Maple Securities USA reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Maple Securities USA sold 1,244 United Therapeutics shares in Q3 2015, an estimated $216K.
  • Maple Securities USA first reported a position in United Therapeutics in Q2 2015 and held it in 1 quarter.
  • Maple Securities USA's United Therapeutics position peaked at $216K in Q2 2015.
  • 372 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.